{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T02:29:53Z","timestamp":1786501793199,"version":"build-2736575974"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.prp.2026.156634","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:05:14Z","timestamp":1785251114000},"page":"156634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immune\u2013angiogenic crosstalk in glioblastoma: Mechanisms and therapeutic opportunities"],"prefix":"10.1016","volume":"286","author":[{"given":"Sumaya Islam","family":"Supty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M. Sertaz","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atia Tanzum Mollik","family":"Riea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Abdul","family":"Momin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md","family":"Sadekuzzaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumaia Islam","family":"Mow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Shiblee Sadik","family":"Sabuj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Khasnobish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1385-2328","authenticated-orcid":false,"given":"Animesh Chandra","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-9353","authenticated-orcid":false,"given":"Md Rashedunnabi","family":"Akanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib1","article-title":"Regulatory mechanisms of STAT3 in GBM and its Impact on TMZ Resistance","volume":"17","author":"Lv","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.prp.2026.156634_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218216","article-title":"Tumor microenvironment in glioblastoma: The central role of the hypoxic-necrotic core","volume":"639","author":"Bayona","year":"2026","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.prp.2026.156634_bib3","first-page":"381","article-title":"Brain and other central nervous system tumor statistics, 2021","volume":"71","author":"Miller","year":"2021","journal-title":"CA a cancer journal clinicians"},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10555-021-09997-9","article-title":"Glioma: molecular signature and crossroads with tumor microenvironment","volume":"41","author":"Barthel","year":"2022","journal-title":"Cancer Metastas-.-. Rev."},{"issue":"10","key":"10.1016\/j.prp.2026.156634_bib5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41578-019-0135-y","article-title":"Dissecting and rebuilding the glioblastoma microenvironment with engineered materials","volume":"4","author":"Wolf","year":"2019","journal-title":"Nat. Rev. Mater."},{"issue":"7","key":"10.1016\/j.prp.2026.156634_bib6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/09506608.2016.1266744","article-title":"Strategies to direct vascularisation using mesoporous bioactive glass-based biomaterials for bone regeneration","volume":"62","author":"Zhou","year":"2017","journal-title":"Int. Mater. Rev."},{"issue":"9","key":"10.1016\/j.prp.2026.156634_bib7","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. & Mol. Med."},{"issue":"2","key":"10.1016\/j.prp.2026.156634_bib8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3390\/cancers16020308","article-title":"Glioma\u2013Immune Cell Crosstalk in Tumor Progression","volume":"16","author":"Elguindy","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trecan.2022.09.005","article-title":"Challenges in glioblastoma research: focus on the tumor microenvironment","volume":"9","author":"Bikfalvi","year":"2023","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","article-title":"Glioblastoma at the crossroads: current understanding and future therapeutic horizons","volume":"10","author":"Singh","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib11","article-title":"Progress of angiogenesis signal pathway and antiangiogenic drugs in nasopharyngeal carcinoma","volume":"17","author":"Zhu","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib12","article-title":"Tumor microenvironment in glioblastoma: Current and emerging concepts","volume":"5","author":"Sharma","year":"2023","journal-title":"Neuro-Oncol. Adv."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/biomedicines14010205","article-title":"The Extracellular Matrix, the Silent \u2018Architect\u2019of Glioma","volume":"14","author":"Rubio","year":"2026","journal-title":"Biomedicines"},{"key":"10.1016\/j.prp.2026.156634_bib14","first-page":"18","article-title":"Distinct tumor immune microenvironmental (TIME) landscapes drive divergent immunotherapy responses in glioblastoma","author":"Weng","year":"2026","journal-title":"Neuro-Oncol. noag0"},{"issue":"3","key":"10.1016\/j.prp.2026.156634_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10456-024-09913-z","article-title":"Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism","volume":"27","author":"Yang","year":"2024","journal-title":"Angiogenesis"},{"key":"10.1016\/j.prp.2026.156634_bib16","article-title":"Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib17","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-026-08497-0","article-title":"PD-1H (VISTA) drives immunosuppressive reprogramming of glioma-associated myeloid cells to promote glioma progression","volume":"24","author":"Guo","year":"2026","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.prp.2026.156634_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2026.1774215","article-title":"Spatiotemporal and metabolic heterogeneity of tumor-associated macrophages in glioblastoma: from single-cell insights to therapeutic targeting","volume":"14","author":"Lu","year":"2026","journal-title":"Front. Cell. Dev. Biol."},{"issue":"12","key":"10.1016\/j.prp.2026.156634_bib19","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.devcel.2025.01.014","article-title":"STAT3-controlled CHI3L1\/SPP1 positive feedback loop demonstrates the spatial heterogeneity and immune characteristics of glioblastoma","volume":"60","author":"Yu","year":"2025","journal-title":"Dev. Cell."},{"issue":"6","key":"10.1016\/j.prp.2026.156634_bib20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/cac2.70016","article-title":"Blocking ITGA5 potentiates the efficacy of anti-PD-1 therapy on glioblastoma by remodeling tumor-associated macrophages","volume":"45","author":"Zhao","year":"2025","journal-title":"Cancer Commun (Lond)"},{"issue":"3","key":"10.1016\/j.prp.2026.156634_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mmr.2026.13952","article-title":"TREM2 in glioma: Reprogramming the immune microenvironment from mechanistic understanding to clinical translation (Review)","volume":"34","author":"Fan","year":"2026","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13046-025-03393-9","article-title":"7aaRGD-a novel SPP1\/integrin signaling-blocking peptide reverses immunosuppression and improves anti-PD-1 immunotherapy outcomes in experimental gliomas","volume":"44","author":"Ellert-Miklaszewska","year":"2025","journal-title":"J. Exp. & Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156634_bib23","article-title":"Current perspectives and trends of CD39-CD73-eAdo\/A2aR research in tumor microenvironment: a bibliometric analysis","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","article-title":"Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives","volume":"17","author":"Lin","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.prp.2026.156634_bib25","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1158\/2326-6066.CIR-23-0959","article-title":"Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways","volume":"12","author":"Skadborg","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.prp.2026.156634_bib26","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.actbio.2024.02.007","article-title":"Nanoparticle-mediated blockade of CXCL12\/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics","volume":"177","author":"Wei","year":"2024","journal-title":"Acta Biomater."},{"issue":"11","key":"10.1016\/j.prp.2026.156634_bib27","article-title":"Lnc-H19-derived protein shapes the immunosuppressive microenvironment of glioblastoma","volume":"5","author":"Chen","year":"2024","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.prp.2026.156634_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156834","article-title":"The possible anti-tumor effects of regulatory T cells plasticity \/ IL-35 in the tumor microenvironment of the major three cancer types","volume":"186","author":"Khalil","year":"2025","journal-title":"Cytokine"},{"issue":"8","key":"10.1016\/j.prp.2026.156634_bib29","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/glia.23309","article-title":"Glioma infiltration and extracellular matrix: key players and modulators","volume":"66","author":"Ferrer","year":"2018","journal-title":"Glia"},{"issue":"6","key":"10.1016\/j.prp.2026.156634_bib30","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3390\/cancers15061879","article-title":"The extracellular matrix in glioblastomas: a glance at its structural modifications in shaping the tumoral microenvironment\u2014a systematic review","volume":"15","author":"Marino","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156634_bib31","article-title":"Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma","volume":"11","author":"Jain","year":"2021","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156634_bib32","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3390\/cancers14051176","article-title":"Current understanding of hypoxia in glioblastoma multiforme and its response to immunotherapy","volume":"14","author":"Park","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib33","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12915-024-02075-w","article-title":"The neglected burden of chronic hypoxia on the resistance of glioblastoma multiforme to first-line therapies","volume":"22","author":"Bou-Gharios","year":"2024","journal-title":"BMC Biol."},{"issue":"9","key":"10.1016\/j.prp.2026.156634_bib34","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3390\/cells11091433","article-title":"The role of extracellular vesicles in metabolic reprogramming of the tumor microenvironment","volume":"11","author":"Fridman","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib35","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.prp.2026.156634_bib36","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00262-024-03689-3","article-title":"A2AR-mediated CXCL5 upregulation on macrophages promotes NSCLC progression via NETosis","volume":"73","author":"Lei","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"8048","key":"10.1016\/j.prp.2026.156634_bib37","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib38","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2320951","article-title":"Lactate\/GPR81 recruits regulatory T cells by modulating CX3CL1 to promote immune resistance in a highly glycolytic gastric cancer","volume":"13","author":"Su","year":"2024","journal-title":"Oncoimmunology"},{"issue":"771","key":"10.1016\/j.prp.2026.156634_bib39","doi-asserted-by":"crossref","first-page":"eadk1168","DOI":"10.1126\/scitranslmed.adk1168","article-title":"Protumoral lipid droplet\u2013loaded macrophages are enriched in human glioblastoma and can be therapeutically targeted","volume":"16","author":"Governa","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib40","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12964-024-01523-y","article-title":"Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages","volume":"22","author":"Tankov","year":"2024","journal-title":"Cell. Commun. Signal."},{"key":"10.1016\/j.prp.2026.156634_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.622615","article-title":"The normal and brain tumor vasculature: morphological and functional characteristics and therapeutic targeting","volume":"12","author":"Guyon","year":"2021","journal-title":"Front. Physiol."},{"issue":"13","key":"10.1016\/j.prp.2026.156634_bib42","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.3390\/cancers13133253","article-title":"New angiogenic regulators produced by TAMs: perspective for targeting tumor angiogenesis","volume":"13","author":"Larionova","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.prp.2026.156634_bib43","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/1535-7163.MCT-22-0595","article-title":"Interplay between extracellular matrix remodeling and angiogenesis in tumor ecosystem","volume":"22","author":"Siddhartha","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.prp.2026.156634_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.831636","article-title":"Cancer metabolism: the role of immune cells epigenetic alteration in tumorigenesis, progression, and metastasis of glioma","volume":"13","author":"Kanwore","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.prp.2026.156634_bib45","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.3390\/ijms22116126","article-title":"Pro-and antiangiogenic factors in gliomas: Implications for novel therapeutic possibilities","volume":"22","author":"Groblewska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.prp.2026.156634_bib46","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3390\/biomedicines10061285","article-title":"The vascular microenvironment in glioblastoma: a comprehensive review","volume":"10","author":"Mosteiro","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.prp.2026.156634_bib47","article-title":"Molecular bases of VEGFR-2-mediated physiological function and pathological role","volume":"8","author":"Wang","year":"2020","journal-title":"Front. Cell. Dev. Biol."},{"issue":"10","key":"10.1016\/j.prp.2026.156634_bib48","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1177\/0271678X17722436","article-title":"The vascular basement membrane in the healthy and pathological brain","volume":"37","author":"Thomsen","year":"2017","journal-title":"J. Cereb. Blood Flow. & Metab."},{"key":"10.1016\/j.prp.2026.156634_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-bioeng-110220-115419","article-title":"Regulation of Tumor Invasion by the Physical Microenvironment: Lessons from Breast and Brain Cancer","volume":"24","author":"Beeghly","year":"2022","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.prp.2026.156634_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1226360","article-title":"Immunotherapies targeting tumor vasculature: challenges and opportunities","volume":"14","author":"Dianat-Moghadam","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156634_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216074","article-title":"Pericytes in the tumor microenvironment","volume":"556","author":"Jiang","year":"2023","journal-title":"Cancer Lett."},{"issue":"13","key":"10.1016\/j.prp.2026.156634_bib52","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.3390\/cancers14133128","article-title":"Dynamic interactions between tumor cells and brain microvascular endothelial cells in glioblastoma","volume":"14","author":"Testa","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.prp.2026.156634_bib53","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1369\/0022155417752676","article-title":"Glioma stem cell niches in human glioblastoma are periarteriolar","volume":"66","author":"Hira","year":"2018","journal-title":"J. Histochem. & Cytochem."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib54","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12885-023-10659-y","article-title":"Characteristics of vasculogenic mimicry and tumour to endothelial transdifferentiation in human glioblastoma: A systematic review","volume":"23","author":"Maddison","year":"2023","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.prp.2026.156634_bib55","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/03602532.2022.2116033","article-title":"Targeting endothelial cell metabolism in cancerous microenvironment: a new approach for anti-angiogenic therapy","volume":"54","author":"Mohammadi","year":"2022","journal-title":"Drug. Metab. Rev."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib56","article-title":"The hidden architects of glioblastoma multiforme: Glioma stem cells","volume":"3","author":"Sahoo","year":"2024","journal-title":"MedCommOncol"},{"issue":"3","key":"10.1016\/j.prp.2026.156634_bib57","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.3390\/cimb46030153","article-title":"Deciphering glioblastoma: fundamental and novel insights into the biology and therapeutic strategies of gliomas","volume":"46","author":"Onciul","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.prp.2026.156634_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.966458","article-title":"Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment","volume":"9","author":"Franson","year":"2022","journal-title":"Front. Med."},{"issue":"2","key":"10.1016\/j.prp.2026.156634_bib59","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/cancers13020210","article-title":"The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment","volume":"13","author":"Haist","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11060-020-03483-y","article-title":"Immune suppression in gliomas","volume":"151","author":"Grabowski","year":"2021","journal-title":"J. neuro-Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156634_bib61","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85935","article-title":"PD-1 marks dysfunctional regulatory T cells in malignant gliomas","volume":"1","author":"Lowther","year":"2016","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib62","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.prp.2026.156634_bib63","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3390\/cells10040893","article-title":"New insights into the multifaceted role of myeloid-derived suppressor cells (MDSCs) in high-grade gliomas: from metabolic reprograming, immunosuppression, and therapeutic resistance to current strategies for targeting MDSCs","volume":"10","author":"Lakshmanachetty","year":"2021","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.prp.2026.156634_bib64","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41590-019-0433-y","article-title":"Mechanisms of immunotherapy resistance: lessons from glioblastoma","volume":"20","author":"Jackson","year":"2019","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.prp.2026.156634_bib65","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s11060-024-04881-2","article-title":"Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions","volume":"171","author":"Badani","year":"2025","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.prp.2026.156634_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1135430","article-title":"Deciphering immune microenvironment and cell evasion mechanisms in human gliomas","volume":"13","author":"Rafii","year":"2023","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2026.156634_bib67","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/cells10030607","article-title":"The role of cytokines and chemokines in shaping the immune microenvironment of glioblastoma: implications for immunotherapy","volume":"10","author":"Yeo","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2019.06.021","article-title":"Pas de deux: control of anti-tumor immunity by cancer-associated inflammation","volume":"51","author":"Shalapour","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.prp.2026.156634_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108750","article-title":"Neurobiology of cancer: adrenergic signaling and drug repurposing","volume":"264","author":"Dong","year":"2024","journal-title":"Pharmacol. & Ther."},{"key":"10.1016\/j.prp.2026.156634_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216234","article-title":"Cancer-associated fibroblasts: key criminals of tumor pre-metastatic niche","volume":"566","author":"Dong","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2026.156634_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1310442","article-title":"Study on the mechanism of MDSC-platelets and their role in the breast cancer microenvironment","volume":"12","author":"Han","year":"2024","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.prp.2026.156634_bib72","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fcell.2020.00351","article-title":"Friend or foe? Recent strategies to target myeloid cells in cancer","volume":"8","author":"Chaib","year":"2020","journal-title":"Front. Cell. Dev. Biol."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib73","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgaf396","article-title":"Role of elevation of glycolysis in tumor-associated macrophages in glioblastoma immune evasion and therapeutic implications","volume":"5","author":"Chen","year":"2026","journal-title":"PNAS Nexus"},{"key":"10.1016\/j.prp.2026.156634_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1676338","article-title":"Advances in tumor-associated macrophage-mediated chemotherapeutic resistance in glioma","volume":"13","author":"Liu","year":"2025","journal-title":"Front. Cell. Dev. Biol."},{"issue":"6","key":"10.1016\/j.prp.2026.156634_bib75","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3390\/ijms21061954","article-title":"Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance","volume":"21","author":"Khan","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156634_bib76","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3389\/fimmu.2020.00737","article-title":"The emerging role of myeloid-derived suppressor cells in the glioma immune suppressive microenvironment","volume":"11","author":"Mi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156634_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112922","article-title":"Immunosuppressive MDSC and Treg signatures predict prognosis and therapeutic response in glioma","volume":"141","author":"Yin","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"ement_4","key":"10.1016\/j.prp.2026.156634_bib78","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/noajnl\/vdae204","article-title":"The glioma microenvironment and its impact on antitumor immunity","volume":"7","author":"Hansen","year":"2025","journal-title":"Neuro-Oncol. Adv."},{"issue":"14","key":"10.1016\/j.prp.2026.156634_bib79","doi-asserted-by":"crossref","first-page":"7979","DOI":"10.3390\/ijms25147979","article-title":"Glioma Stem Cells as Promoter of Glioma Progression: A Systematic Review of Molecular Pathways and Targeted Therapies","volume":"25","author":"Agosti","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib80","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13287-025-04352-z","article-title":"Glioma stem cells: drivers of tumor progression and recurrence","volume":"16","author":"He","year":"2025","journal-title":"Stem Cell. Res. Ther."},{"issue":"22","key":"10.1016\/j.prp.2026.156634_bib81","doi-asserted-by":"crossref","first-page":"12608","DOI":"10.3390\/ijms222212608","article-title":"Hypoxia: The Cornerstone of Glioblastoma","volume":"22","author":"Dom\u00e8nech","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.prp.2026.156634_bib82","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s10495-026-02275-5","article-title":"Enhancing the efficacy of VEGF inhibitors by co-inhibition of HIF in the treatment of glioblastoma","volume":"31","author":"Harbi","year":"2026","journal-title":"Apoptosis"},{"key":"10.1016\/j.prp.2026.156634_bib83","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fonc.2017.00024","article-title":"The unique molecular and cellular microenvironment of ovarian cancer","volume":"7","author":"Worzfeld","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156634_bib84","first-page":"1","article-title":"Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity","author":"Moreno-Sanchez","year":"2026","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib85","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1186\/s12967-024-05301-9","article-title":"The tumour microenvironment, treatment resistance and recurrence in glioblastoma","volume":"22","author":"White","year":"2024","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.prp.2026.156634_bib86","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/path.5080","article-title":"Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules","volume":"245","author":"He","year":"2018","journal-title":"J. Pathol."},{"issue":"6","key":"10.1016\/j.prp.2026.156634_bib87","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ccell.2023.04.010","article-title":"Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma","volume":"41","author":"Ramachandran","year":"2023","journal-title":"Cancer Cell."},{"issue":"17","key":"10.1016\/j.prp.2026.156634_bib88","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.3390\/cancers15174257","article-title":"Vascular immune evasion of mesenchymal glioblastoma is mediated by interaction and regulation of VE-cadherin on PD-L1","volume":"15","author":"Luo","year":"2023","journal-title":"Cancers"},{"issue":"583","key":"10.1016\/j.prp.2026.156634_bib89","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb6731","article-title":"Dual role of endothelial Myct1 in tumor angiogenesis and tumor immunity","volume":"13","author":"Kabir","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib90","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.prp.2026.156634_bib91","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3892\/ol.2022.13489","article-title":"Immunosuppressive effects of vascular endothelial growth factor","volume":"24","author":"Ribatti","year":"2022","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.prp.2026.156634_bib92","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156634_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1682030","article-title":"From neuroinflammation to gliomagenesis: immune drivers of malignant transformation in the CNS","volume":"16","author":"Bao","year":"2025","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.prp.2026.156634_bib94","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708253","article-title":"Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer","volume":"13","author":"Khan","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.prp.2026.156634_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1171794","article-title":"Regulation of tumor angiogenesis by the crosstalk between innate immunity and endothelial cells","volume":"13","author":"Ebeling","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156634_bib96","article-title":"Tumor immune-vascular crosstalk: synergy and translation of immune checkpoint inhibitors and anti-angiogenic agents in melanoma","volume":"17","author":"Xie","year":"2026","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib97","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41419-025-07444-z","article-title":"Tumor vascular endothelial cells promote immune escape by upregulating PD-L1 expression via crosstalk between NF-\u03baB and STAT3 signaling pathways in nasopharyngeal carcinoma","volume":"16","author":"Wang","year":"2025","journal-title":"Cell. Death & Dis."},{"issue":"7","key":"10.1016\/j.prp.2026.156634_bib98","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010926","article-title":"Anti-galectin-9 therapy synergizes with EGFR inhibition to reprogram the tumor microenvironment and overcome immune evasion","volume":"13","author":"Linghu","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib99","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.prp.2026.156634_bib100","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/med.21771","article-title":"The role of hypoxia-inducible factor 1 in tumor immune evasion","volume":"41","author":"You","year":"2021","journal-title":"Med. Res. Rev."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib101","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-023-01761-7","article-title":"Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF\/FGFR signaling in tumor microenvironment","volume":"22","author":"Ruan","year":"2023","journal-title":"Mol. Cancer"},{"issue":"13","key":"10.1016\/j.prp.2026.156634_bib102","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.3390\/ijms22136671","article-title":"VEGF regulation of angiogenic factors via inflammatory signaling in myeloproliferative neoplasms","volume":"22","author":"Suboti\u010dki","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.prp.2026.156634_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153686","article-title":"Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade","volume":"13","author":"Ho","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib104","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s10238-025-01751-7","article-title":"Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective","volume":"25","author":"Sherafat","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.prp.2026.156634_bib105","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fphar.2022.1077468","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives [Review]","volume":"13","author":"Liu","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib106","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s10143-025-03536-8","article-title":"The safety and efficacy of VEGFR tyrosine kinase inhibitors for patients with gliomas: a systematic review, meta-analysis, and a specific analysis on glioblastoma","volume":"48","author":"Habibi","year":"2025","journal-title":"Neurosurg. Rev."},{"key":"10.1016\/j.prp.2026.156634_bib107","article-title":"Angiogenesis and Resistance Mechanisms in Glioblastoma: Targeting Alternative Vascularization Pathways to Overcome Therapy Resistance","author":"Beylerli","year":"2025","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib108","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12935-024-03293-6","article-title":"MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1\/PD-L1 and CTLA-4 pathways","volume":"24","author":"Zabeti Touchaei","year":"2024","journal-title":"Cancer Cell. Int."},{"issue":"5","key":"10.1016\/j.prp.2026.156634_bib109","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2026.156634_bib110","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3390\/cancers13040806","article-title":"Tumor heterogeneity: a great barrier in the age of cancer immunotherapy","volume":"13","author":"El-Sayes","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib111","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40164-023-00372-8","article-title":"Increasing cure rates of solid tumors by immune checkpoint inhibitors","volume":"12","author":"Ma","year":"2023","journal-title":"Exp. Hematol. & Oncol."},{"issue":"7","key":"10.1016\/j.prp.2026.156634_bib112","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.prp.2026.156634_bib113","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.70993","article-title":"Exploring Novel Compounds and Nanocomplexes to Target Cellular and Molecular Interactions in the Glioblastoma Microenvironment","volume":"40","author":"Oriquat","year":"2026","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.prp.2026.156634_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1613332","article-title":"Vaccine therapies for glioma: clinical frontiers and potential breakthrough","volume":"15","author":"Xing","year":"2025","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib115","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41698-024-00753-0","article-title":"CAR-T cell therapy for the treatment of adult high-grade gliomas","volume":"8","author":"Park","year":"2024","journal-title":"NPJ Precis. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib116","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41540-025-00642-7","article-title":"Mathematical modeling of combinatorial antigen targeting with multiple CAR T-cell products for glioblastoma treatment","volume":"12","author":"Li","year":"2026","journal-title":"npj Syst. Biol. Appl."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib117","doi-asserted-by":"crossref","first-page":"9718","DOI":"10.1038\/s41467-024-54129-w","article-title":"Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRP\u03b3-derived CD47 blocker","volume":"15","author":"Martins","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib118","article-title":"Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma","volume":"5","author":"Schmidts","year":"2023","journal-title":"Neurooncol Adv."},{"key":"10.1016\/j.prp.2026.156634_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102684","article-title":"Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase","volume":"73","author":"Shen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.prp.2026.156634_bib120","doi-asserted-by":"crossref","DOI":"10.1093\/oons\/kvad008","article-title":"Glioblastoma modeling with 3D organoids: progress and challenges","volume":"2","author":"Wang","year":"2023","journal-title":"Oxf. Open. Neurosci."},{"issue":"11","key":"10.1016\/j.prp.2026.156634_bib121","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.apsb.2020.04.004","article-title":"The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy","volume":"10","author":"Yang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.prp.2026.156634_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1476565","article-title":"Mechanistic studies of tumor-associated macrophage immunotherapy","volume":"15","author":"Cao","year":"2024","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.prp.2026.156634_bib123","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70223","article-title":"A Phosphatidylinositol 3-Kinase Gamma Inhibitor Enhances Anti-Programmed Death-1\/Programmed Death Ligand-1 Antitumor Effects by Remodeling the Tumor Immune Microenvironment of Ovarian Cancer","volume":"6","author":"Jiang","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.prp.2026.156634_bib124","article-title":"CD47\u2013SIRP\u03b1-targeted therapeutics: status and prospects","volume":"13","author":"Maute","year":"2022","journal-title":"Immuno-Oncol. Technol."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib125","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11481-025-10250-1","article-title":"Lipid-Metabolically Active TREM2(high) Microglia\u2011Derived Macrophages Predict Poor Prognosis and Represent an Immunotherapeutic Target in Glioma","volume":"20","author":"Li","year":"2025","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib126","doi-asserted-by":"crossref","DOI":"10.1002\/INMD.20230025","article-title":"Anti-angiogenic therapy enhances cancer immunotherapy: Mechanism and clinical application","volume":"2","author":"Li","year":"2024","journal-title":"Interdiscip. Med."},{"issue":"604","key":"10.1016\/j.prp.2026.156634_bib127","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc8922","article-title":"Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy","volume":"13","author":"Sun","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.prp.2026.156634_bib128","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-20-2500","article-title":"Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma","volume":"27","author":"Nayak","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.prp.2026.156634_bib129","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/neuonc\/noy054","article-title":"Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma","volume":"20","author":"Ellingson","year":"2018","journal-title":"Neuro-Oncol."},{"issue":"3","key":"10.1016\/j.prp.2026.156634_bib130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/neuonc\/nov180","article-title":"Current status and future directions of anti-angiogenic therapy for gliomas","volume":"18","author":"Wick","year":"2016","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.prp.2026.156634_bib131","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3390\/cancers15030830","article-title":"Exploring the Past, Present, and Future of Anti-Angiogenic Therapy in Glioblastoma","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156634_bib132","article-title":"Red blood cell-derived materials for cancer therapy: construction, distribution, and applications","volume":"24","author":"Ding","year":"2024","journal-title":"Mater. Today Bio"},{"issue":"19","key":"10.1016\/j.prp.2026.156634_bib133","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26199362","article-title":"Artificial Intelligence-Driven Multi-Omics Approaches in Glioblastoma","volume":"26","author":"Morello","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156634_bib134","article-title":"Single-cell and spatial transcriptomic insights into glioma cellular heterogeneity and metabolic adaptations","volume":"16","author":"Fu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156634_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104239","article-title":"Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM","volume":"83","author":"Xiong","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.prp.2026.156634_bib136","author":"Carretero Coca","year":"2024","journal-title":"Pericyte phenotype Switch. alleviates Immunosuppr. sensitizes Vasc. Tumors Immunother. Preclin. Models"},{"issue":"5","key":"10.1016\/j.prp.2026.156634_bib137","doi-asserted-by":"crossref","first-page":"353","DOI":"10.20892\/j.issn.2095-3941.2023.0061","article-title":"Development of glioblastoma organoids and their applications in personalized therapy","volume":"20","author":"Xu","year":"2023","journal-title":"Cancer Biol. Med."},{"issue":"3","key":"10.1016\/j.prp.2026.156634_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109111","article-title":"Modeling the precise interaction of glioblastoma with human brain region-specific organoids","volume":"27","author":"Fan","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.prp.2026.156634_bib139","doi-asserted-by":"crossref","DOI":"10.2174\/0115665232400556251120095720","article-title":"Glioblastoma Organoid Technology: Approach to Target the Complex Tumor Microenvironment with Promising Drug Responsiveness","author":"Bisht","year":"2026","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.prp.2026.156634_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116436","article-title":"CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment","volume":"174","author":"Kong","year":"2024","journal-title":"Biomed. & Pharmacother."},{"issue":"7","key":"10.1016\/j.prp.2026.156634_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104570","article-title":"Multimodal imaging of the dynamic brain tumor microenvironment during glioblastoma progression and in response to treatment","volume":"25","author":"Zomer","year":"2022","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib142","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s40478-024-01888-8","article-title":"Towards integrating imaging and immunology in glioblastoma: mapping blood immune system metrics to tumor magnetic resonance image data","volume":"12","author":"Heugenhauser","year":"2024","journal-title":"Acta Neuropathol. Commun."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib143","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1038\/s41598-024-55296-y","article-title":"ImmunoPET imaging of TIGIT in the glioma microenvironment","volume":"14","author":"Vincze","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib144","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13040-023-00349-7","article-title":"DeepAutoGlioma: a deep learning autoencoder-based multi-omics data integration and classification tools for glioma subtyping","volume":"16","author":"Munquad","year":"2023","journal-title":"BioData Min."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib145","article-title":"Leveraging TME features and multi-omics data with an advanced deep learning framework for improved Cancer survival prediction","volume":"15","author":"Fan","year":"2025","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.prp.2026.156634_bib146","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/bfgp\/elae013","article-title":"A comprehensive review of machine learning techniques for multi-omics data integration: challenges and applications in precision oncology","volume":"23","author":"Acharya","year":"2024","journal-title":"Brief. Funct. Genom."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib147","first-page":"12","article-title":"The epigenetic mechanisms involved in the treatment resistance of glioblastoma","volume":"8","author":"Shahani","year":"2025","journal-title":"Cancer Drug. Resist."},{"key":"10.1016\/j.prp.2026.156634_bib148","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1530305","article-title":"Molecular biology of the deadliest cancer - glioblastoma: what do we know?","volume":"16","author":"Ismailov","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156634_bib149","doi-asserted-by":"crossref","DOI":"10.26599\/NR.2026.94908472","article-title":"Nanomedicine-enabled epigenetic therapy for glioblastoma: Overcome the blood-brain barrier and therapeutic resistance","author":"Yang","year":"2026","journal-title":"Nano Res."},{"key":"10.1016\/j.prp.2026.156634_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1705234","article-title":"Overcoming the blood-brain barrier: targeted delivery strategies for gliomas","volume":"16","author":"Du","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib151","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12987-025-00695-0","article-title":"Focused ultrasound-mediated temozolomide delivery into intact blood\u2013brain barrier tissue improves survival in patient-derived xenograft model of glioblastoma","volume":"22","author":"Shin","year":"2025","journal-title":"Fluids Barriers CNS"},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib152","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol33010019","article-title":"Combination Cancer Therapy and Reference Models for Assessing Drug Synergy in Glioblastoma","volume":"33","author":"Sinyavskiy","year":"2025","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156634_bib153","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12951-025-03112-8","article-title":"Synergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade","volume":"23","author":"Liu","year":"2025","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.prp.2026.156634_bib154","first-page":"2025","article-title":"Overcoming immune evasion with innovative multi-target approaches for glioblastoma [Mini Review]","volume":"16","author":"Su","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156634_bib155","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3389\/fimmu.2025.1661327","article-title":"Targeting the neuroimmune axis in glioblastoma: emerging strategies for precision immunotherapy [Mini Review]","volume":"16","author":"Lang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156634_bib156","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3389\/fimmu.2025.1690464","article-title":"Recent advances in immunotherapy for gliomas: overcoming barriers and advancing precision strategies [Review]","volume":"16","author":"Jabri","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156634_bib157","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1487610","article-title":"Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T02:20:03Z","timestamp":1786501203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826002876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":157,"alternative-id":["S0344033826002876"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156634","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune\u2013angiogenic crosstalk in glioblastoma: Mechanisms and therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156634"}}